KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovoCure (NVCR) EBITDA (2016 - 2025)

Historic EBITDA for NovoCure (NVCR) over the last 12 years, with Q3 2025 value amounting to -$36.0 million.

  • NovoCure's EBITDA fell 1224.29% to -$36.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$176.7 million, marking a year-over-year decrease of 1120.33%. This contributed to the annual value of -$170.5 million for FY2024, which is 2678.49% up from last year.
  • According to the latest figures from Q3 2025, NovoCure's EBITDA is -$36.0 million, which was down 1224.29% from -$39.5 million recorded in Q2 2025.
  • NovoCure's 5-year EBITDA high stood at -$88000.0 for Q1 2021, and its period low was -$63.3 million during Q4 2024.
  • For the 5-year period, NovoCure's EBITDA averaged around -$34.2 million, with its median value being -$36.0 million (2025).
  • In the last 5 years, NovoCure's EBITDA surged by 9739.72% in 2021 and then plummeted by 737506.2% in 2023.
  • Quarter analysis of 5 years shows NovoCure's EBITDA stood at -$23.4 million in 2021, then tumbled by 83.68% to -$43.0 million in 2022, then fell by 20.33% to -$51.7 million in 2023, then dropped by 22.41% to -$63.3 million in 2024, then skyrocketed by 43.1% to -$36.0 million in 2025.
  • Its EBITDA was -$36.0 million in Q3 2025, compared to -$39.5 million in Q2 2025 and -$37.9 million in Q1 2025.